Sex differences in efficacy and safety of PCSK9 monoclonal antibodies: A real-world registry

• Published in: Atherosclerosis Vol. 384; p. 117108
• Main Authors: Galema-Boers, Annette M.H., Mulder, Janneke W.C.M., Steward, Kim, Roeters van Lennep, Jeanine E.
• Format: Journal Article
• Language: English
• Published: Ireland Elsevier B.V 01-11-2023
• Subjects: Cardiovascular disease; Efficacy; Lipid lowering therapy; PCSK9 inhibitors; Safety; Sex differences; Lipid lowering therapy; PCSK9 inhibitors; Sex differences; Cardiovascular disease; Efficacy; Safety
• ISSN: 0021-9150; 1879-1484
• DOI: 10.1016/j.atherosclerosis.2023.03.013

Proprotein convertase subtilisin/kexin 9 monoclonal antibodies (PCSK9 mAbs) reduce low-density lipoprotein (LDL-c) with a favourable safety profile. Available data from PCSK9 antibody trials suggest LDL-c reduction is lower in women compared to men. Data in real-world setting is scarce. The aim of this study was to assess sex differences in efficacy and safety of PCSK9 antibodies in clinical care.
All patients starting with evolocumab or alirocumab in our lipid clinic were included in a prospective registry. We collected clinical information, including baseline and follow-up mean LDL-C levels after initiation of PCSK9 mAbs treatment. In addition, side effects and PCSK9 mAbs discontinuation were recorded.
We analysed 436 patients (209 women), mean age 58 ± 11 years. Women had higher baseline LDL-c levels compared to men (4.7 ± 1.6 mmol/L vs 4.1 ± 1.4 mmol/L, p < 0.01). PCSK9 mAbs resulted in less relative LDL-c reduction in women compared to men (50% vs 61% p<0.01), but equal absolute LDL-c reduction (respectively 2.3 ± 1.3 mmol/L vs 2.5 ± 1.1 mmol/L, p = 0.087). Women less often reached LDL-c target levels than men (50% vs 72%). No sex differences were observed in reporting of side effects (women 32% vs men 27% p = 0.26) or PCSK9 mAbs discontinuation (women 13% vs men 10%, p = 0.46).
In clinical practice, PCSK9 mAbs are less effective in reducing LDL-c levels in women compared to men and equally safe, implying the importance of sex differences in PCSK9 metabolism.
[Display omitted]
•LDL-cholesterol PCSK9 mAbs reduction is less in women compared to men.•No sex differences were observed in reporting of side effects due to PCSK9 mAbs.•In real-world setting, discontinuation of PCSK9 mAbs is similar between sexes.